Every year researchers make exciting new progress towards a better understanding of the causes and risk factors for esophageal cancer and Barrett’s esophagus. As 2014 comes to close let’s take a look at two new studies that may have an important impact on how we detect disease in the esophagus in the future. Read the rest of this entry »
We are working hard to bring Cellvizio to physicians and surgeons around the world, and now a hospital in Macon, Georgia is using our technology to help identify pre-cancerous and cancerous cells in patients with gastroesophageal reflux disease (GERD).
It’s estimated that approximately 20 percent of people in the US experience reflux symptoms at least weekly. Surgery is often the only alternative for many of these patients. But prior to anti-reflux surgery, steps must be taken to identify and treat pre-cancerous or cancerous cells.
“As we prepare patients for anti-reflux surgery, Cellvizio makes it possible for us to rule-out the presence of pre-cancerous cells with more diagnostic accuracy and gives us the ability to perform improved surgical intervention. The technology also plays an important role in monitoring for the presence of cancerous cells after the procedure.” – Joseph J. Burnette, M.D.
Surgeons at Coliseum Northside Hospital have successfully completed over 100 endomicroscopic procedures in patients with GERD since they started using Cellvizio in September 2014. Take a look at some of their feedback:
“Instead of taking biopsy tissue to a microscope to identify cancer in patients with GERD, with Cellvizio we are taking the microscope to the tissue. We can often identify cancer in real-time, which is a tremendous advantage for patients and for treatment outcomes.” – V. John Bagnato, M.D.
While GERD patients typically present with acid reflux symptoms, people impacted by Barrett’s esophagus often do not. Barrett’s can only be diagnosed by an upper endoscopy evaluation of the esophagus and a biopsy. With Cellvizio, physicians can examine the tissue during the endoscopy, potentially reducing the need for a separate pathological evaluation.
Our goal is to help physicians see cancer faster. The use of Cellvizio in Georgia is a step in the right direction and we are excited to bring this technology to even more patients in the future.